Retatrutide vs Zepbound for Diabetes: Which Is Better in 2026?

🔬 The Verdict: Retatrutide Wins for Weight Loss, Zepbound Slightly Ahead for A1C

Based on the latest TRANSCEND-T2D-1 trial results announced today (March 19, 2026), here's how these two Lilly drugs compare for Type 2 diabetes:

Metric	Retatrutide 12mg	Zepbound (Tirzepatide)	Winner
Weight Loss (40 weeks)	16.8% (36.6 lbs)	11-13%	🏆 Retatrutide
A1C Reduction	1.7-2.0%	>2%	🏆 Zepbound (slight edge)
Discontinuation Rate	5%	Varies (~10-15%)	🏆 Retatrutide
FDA Approval	Not yet (late 2026)	✅ Approved	🏆 Zepbound
Mechanism	Triple agonist (GLP-1/GIP/Glucagon)	Dual agonist (GLP-1/GIP)	🏆 Retatrutide

Bottom Line: If you need maximum weight loss, wait for retatrutide. If you need strong A1C control NOW, choose Zepbound.

📊 Weight Loss Comparison (Diabetes Trials)

Retatrutide (TRANSCEND-T2D-1, 2026)

• 16.8% average weight loss at 12mg dose (40 weeks)
• 36.6 lbs lost for patients who stayed on treatment
• 15.3% weight loss including discontinuations
• No plateau observed at 40 weeks

Zepbound (SURPASS Trials)

• 13.1% weight loss in SURPASS-2 (40 weeks)
• 11% weight loss in SURPASS-1 (40 weeks)
• Both at highest dose (15mg tirzepatide)

The Difference

Retatrutide delivers 3-6% more weight loss than Zepbound in diabetes patients. That translates to:

• ~10-15 extra pounds lost over 40 weeks
• Continued weight loss trajectory (no plateau)

Why? The addition of glucagon (third hormone) enhances:

• Fat burning
• Metabolic rate
• Appetite suppression

🩸 A1C Reduction Comparison

Retatrutide (TRANSCEND-T2D-1)

• 1.7% to 2.0% A1C reduction across doses
• Starting A1C: 7%-9.5%
• 40 weeks
• Patients NOT on other diabetes meds

Zepbound (SURPASS Trials)

• >2% A1C reduction in SURPASS-1 and SURPASS-2
• Starting A1C: ~7.9-8.3%
• 40 weeks
• Similar patient populations

The Verdict

Zepbound has a slight edge for pure A1C reduction (~0.2-0.3% more), but retatrutide is very competitive.

Key Quote from Lilly:

"Patients who want to regulate their blood sugar could benefit from either Zepbound or retatrutide. But if they are looking to lose more weight, the latter might be a better option."
— Ken Custer, President, Lilly Cardiometabolic Health

💊 How They Work: Triple vs Dual Agonist

Retatrutide (Triple Agonist)

Targets 3 hormones:

1. GLP-1 — Slows digestion, reduces appetite
2. GIP — Enhances insulin, reduces glucagon
3. Glucagon — Burns fat, increases metabolism

Effect: More potent weight loss, competitive blood sugar control

Zepbound (Dual Agonist)

Targets 2 hormones:

1. GLP-1 — Slows digestion, reduces appetite
2. GIP — Enhances insulin, reduces glucagon

Effect: Strong A1C reduction, good weight loss

Why Glucagon Matters

The glucagon receptor in retatrutide:

• Increases energy expenditure (burns more calories)
• Enhances fat oxidation (fat burning)
• Prevents weight loss plateau
• May improve liver fat (NASH/MASH)

This is why retatrutide delivers superior weight loss without sacrificing blood sugar control.

😷 Side Effects Comparison

Retatrutide (TRANSCEND-T2D-1, March 2026)

GI Side Effects:

• Nausea: 26.5%
• Diarrhea: 22.8%
• Vomiting: 17.6%
• Dysesthesia (nerve sensation): Low rates

Discontinuation: 5% due to side effects

Zepbound (SURPASS Trials)

GI Side Effects:

• Nausea: 25-30%
• Diarrhea: 20-25%
• Vomiting: 10-15%

Discontinuation: ~10-15% due to side effects (varies by trial)

The Winner: Retatrutide (Lower Discontinuation)

Only 5% of patients stopped retatrutide due to side effects vs 10-15% for Zepbound in similar trials.

Why? Possibly:

• Better titration schedule
• Glucagon may reduce GI side effects
• Newer formulation
• Patient selection in trials

🎯 Who Should Choose Which Drug?

Choose Retatrutide If:

• ✅ Weight loss is your top priority (diabetes + obesity)
• ✅ You've plateaued on Zepbound or Wegovy
• ✅ You want the most potent option available
• ✅ You can wait until late 2026/early 2027 for approval
• ✅ You're willing to pay a premium for better results

Choose Zepbound If:

• ✅ A1C control is your top priority (slightly better than retatrutide)
• ✅ You need treatment NOW (FDA approved)
• ✅ You want proven, established medication
• ✅ Your insurance covers it (Mounjaro for diabetes)
• ✅ You prefer dual agonist (less experimental)

📅 Availability Timeline

Zepbound (Tirzepatide)

• ✅ Available NOW (approved May 2023 for obesity, 2022 for diabetes as Mounjaro)
• ✅ Widely covered by insurance for diabetes
• ✅ Compounded versions available ($250-400/month)

Retatrutide

• ⏳ Not yet approved (in Phase 3 trials)
• ⏳ 7 more trials completing in 2026
• ⏳ FDA submission: Expected late 2026
• ⏳ Approval: Late 2026 to early 2027
• ⏳ Launch: Q1 2027 estimated

Can't wait? Start with Zepbound/Mounjaro now, then switch to retatrutide when available.

❓ FAQs

Can I take retatrutide and Zepbound together?

No. Both target GLP-1 and GIP receptors. Combining them would:

• Increase side effects
• Not add benefits
• Be off-label and dangerous

Which is safer: retatrutide or Zepbound?

Similar safety profiles. Both cause:

• GI side effects (nausea, diarrhea, vomiting)
• Rare serious risks (pancreatitis, gallbladder issues)

Retatrutide has lower discontinuation rates (5% vs 10-15%), suggesting better tolerability.

How much weight can I expect to lose?

Zepbound (Mounjaro): 11-13% in diabetes trials, 15-21% in obesity trials
Retatrutide: 16.8% in diabetes trials, 24-28% in obesity trials (TRIUMPH-4)

Retatrutide delivers ~5-7% more weight loss on average.

✅ Bottom Line: Which Should You Choose?

Priority	Best Choice	Why
Maximum weight loss	🏆 Retatrutide (when available)	16.8% vs 11-13% in diabetes trials
Best A1C reduction	🏆 Zepbound (slight edge)	>2% vs 1.7-2%
Available now	🏆 Zepbound	FDA approved, widely available
Fewest side effects	🏆 Retatrutide	Only 5% discontinued
Lowest cost	🏆 Zepbound (compounded)	$250-400/month vs future premium pricing
Most proven	🏆 Zepbound	3+ years real-world data
Most potent	🏆 Retatrutide	Triple agonist mechanism

Can't decide? Start with Zepbound now, then reassess when retatrutide launches in late 2026/early 2027.

Last updated: March 19, 2026
Sources: Lilly TRANSCEND-T2D-1 trial (March 2026), SURPASS trials, CNBC, STAT News